Triphase Accelerator is a privately held drug development accelerator that acquires and develops novel therapeutics. Triphase in-licenses clinically enabled oncology assets with high-value potential and develops them in a shared risk model to proof of concept (POC), then out-licenses or sells the product to realize value. Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of proof of concept in important new cancer therapeutics of mutual interest. The Triphase management team is deeply knowledgeable with significant experience in drug development. Together with the founding organizations Ontario Institute of Cancer Research (OICR) and MaRS Innovation, and supported by MaRS Discovery District along with strategic oncology partnerships, Triphase has formed a unique partnership to produce proof-of-concept data for investors, partners, regulators, payers, and ultimately prescribers and patients.Something looks off?